Pharmacogenetic Testing

Millennium PGT℠ is a non-invasive genetic test utilizing an oral swab to identify how a patient’s genetic profile may impact his or her response to certain medications. Two patients, with the same diagnosis and prescribed the same medication and dose, may exhibit significantly different clinical responses.

The information from the test may provide health care providers a faster and more effective path to optimal medication management.

PGT lab

How it Works


DNA swab sample

Collect Sample

A swab is used to collect a DNA sample from oral fluid

DNA specimen

Run Test

Our specialty lab performs genetic testing on the specimen

MAPP report

MAPP® Report

The DNA is analyzed and a report is generated with results interpretation

Clinical support pinpoint

Clinical Support

Pharmacists and genetic scientists are available for clinical guidance

Genes and Medications


Millennium PGT analyzes clinically relevant genetic variants for 14 genes related to medication response to help clinicians individualize prescribing decisions. The Millennium Analysis of Patient Phenotype (MAPP) Report provides clinicians with evidence based and clinically actionable information to support medication decisions for over 40 commonly prescribed medications across 12 medication classes.

Medication Classes


Addiction Therapy
Anticoagulants
Anticonvulsants
Antidepressants, SSRIs/SNRIs
Antidepressants, TCAs
Antipsychotics

ADHD Therapy
Benzodiazepines
Muscle Relaxants
NSAIDs
Opioids
Platelet Inhibitors

Genes


COMT
CYP2B6
CYP2C19
CYP2C9
CYP2D6
CYP3A4
CYP3A5

DRD2
HLA-B
HTR2C
MTHFR
OPRM1
UGT2B15
VKORC1

Millennium PGT MAPP Report
It’s as easy as 1-2-3!


The Millennium Analysis of Patient Phenotype (MAPP) Report provides clinicians with evidence-based and clinically actionable genetic information to support medication decisions. It can be broken down into three main sections:

1. Laboratory Test Results:
Indicates which gene tests were ordered and the corresponding test results.

2. Current Medication Summary:
An interpretation of your patient’s genetic test results as it relates to his/her current reported medications, highlighting medication(s) that may need attention, and relevant CYP450 drug-drug interactions.

3. Medication Selection Guide:
An objective tool that can be used to inform prescribing decisions according to the patient’s genetic test results.

Sample MAPP report

Attention Needed

Identifies medications that may have a high clinical impact based on the patient’s genetic test results.

Caution

Identifies medications that may have moderate clinical impact based on the patient’s genetic test results.

Minimal Impact

Identifies medications in which the patient is likely to have a typical response based on patient’s genetic test results.

Potential Benefit

Identifies medications for which the patient is likely to have an improved or enhanced response based on patient’s genetic test results.

Drug-Drug Interaction

Identifies potential cytochrome P450 interactions based on patient’s reported medications.

Pharmacogenetics Results Integrated with UDT RADAR® Report


Millennium PGT results are integrated with Millennium UDT results to enhance medication monitoring.

Testimonials


Dr. Helman’s Story

Dr. Manya B. Helman’s patient Lisa suffers from chronic pain and for over 14 years, she tried many medications with minimal pain relief. Millennium PGT helped Dr. Helman find a medication regimen that worked for Lisa.

Dr. Castillo-Armas’ Story

Dr. Edgar Castillo-Armas’ patient Brian suffered from depression for 25 years, and like many other mental health patients, he was prescribed many medications that did not work for him. Find out how Millennium PGT helped Dr. Castillos-Armas find a medication that was effective for Brian.

How to Order



Millennium Health, LLC tests were developed and their performance characteristics determined by Millennium Health. These tests have not been cleared or approved by the US Food and Drug Administration. FDA clearance or approval is not required for clinical use. Millennium Health is regulated under CLIA as qualified to perform high-complexity testing, and is accredited by the College of American Pathologists (CAP). These tests are used for clinical purposes and should not be regarded as investigational or for research. The test results should be used with other clinical and diagnostic findings for patient case management.